Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2012
03/27/2012US8143263 Therapeutic agents
03/27/2012US8143262 7-(3′,4′-Dialkoxyphenyl)[1,2,4]-triazolo[1,5-A]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same
03/27/2012US8143261 Thiazolo (4,5-D) pyrimidine compounds
03/27/2012US8143259 Cold menthol receptor antagonists
03/27/2012US8143257 Substituted phenols as active agents inhibiting VEGF production
03/27/2012US8143256 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics
03/27/2012US8143255 Heteroalkyl linked pyrimidine derivatives
03/27/2012US8143253 Organic compounds
03/27/2012US8143252 Tetrahalogenated compounds useful as inhibitors of angiogenesis
03/27/2012US8143251 Triazolotriazines as kinase inhibitors
03/27/2012US8143250 6-7,dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
03/27/2012US8143249 Prodrugs of A2B adenosine receptor antagonists
03/27/2012US8143248 Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use
03/27/2012US8143247 Combinations for the treatment of diseases involving cell proliferation
03/27/2012US8143246 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
03/27/2012US8143245 Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2, and M3 receptors
03/27/2012US8143244 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
03/27/2012US8143243 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester
03/27/2012US8143242 Malonamide derivatives with antithrombotic activity
03/27/2012US8143241 DNA damage repair inhibitors for treatment of cancer
03/27/2012US8143240 17α, 21-dihydroxypregnene esters as antiandrogenic agents
03/27/2012US8143239 Composition for inhalation
03/27/2012US8143238 Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin D compound
03/27/2012US8143237 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
03/27/2012US8143236 For reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, chemotherapy-associated toxicities; nucleosides
03/27/2012US8143235 Use of dietary fibres against muscle wasting
03/27/2012US8143234 Nervous system disorders; administering exogenous uridine compound
03/27/2012US8143233 RNA aptamers and methods for identifying the same
03/27/2012US8143231 Method of reducing HIV-replication in human body tissue
03/27/2012US8143230 Compounds and methods for modulating expression of PCSK9
03/27/2012US8143229 Method for production of a transformed cell
03/27/2012US8143227 Azithromycin for treatment of skin disorders
03/27/2012US8143226 Tyrosine kinase receptor antagonists and methods of treatment for breast cancer
03/27/2012US8143223 Cytoprotection by means of phosphotyrosine
03/27/2012US8143057 Chelating agents and highly luminescent and stable chelates and their use
03/27/2012US8142819 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
03/27/2012US8142817 Composition for restoration of age related tissue loss in the face or selected areas of the body
03/27/2012US8142811 Controlled release hydrocodone formulations
03/27/2012US8142810 Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
03/27/2012US8142799 High potency clinical anti-craving treatment and method of use
03/27/2012US8142777 Monoclonal antibody specific to colon stimulating factor for use in treatment and prevention of rheumatoid arthritis
03/27/2012US8142763 Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
03/27/2012US8142714 Aqueous solution containing surfactants; alkaline pH; destroying prions
03/27/2012CA2709997C Pirfenidone treatment for patients with atypical liver function
03/27/2012CA2682329C Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
03/27/2012CA2676456C Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
03/27/2012CA2667068C 2-pyridinecarboxamide derivative having gk-activating effect
03/27/2012CA2632542C Topical anti-microbial compositions
03/27/2012CA2603671C Insp163 polypeptides for the treatment or prevention of cancer and arthritis
03/27/2012CA2595363C Methods and materials with trans-clomiphene for the treatment of male infertility
03/27/2012CA2554642C Bicyclic carbonyl amino derivatives as chemokine receptor antagonists
03/27/2012CA2544193C A2b adenosine receptor antagonists
03/27/2012CA2540917C Polyarginine-modified liposome having nuclear entry ability
03/27/2012CA2540541C Alkoxy substituted imidazoquinolines
03/27/2012CA2538750C Method for configuring air-core photonic-bandgap fibers free of surface modes
03/27/2012CA2532347C Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
03/27/2012CA2529007C Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
03/27/2012CA2527141C Polyhydroxy phenols and their use in binding p-selectin
03/27/2012CA2526991C Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor
03/27/2012CA2524898C 6-arylmethyl-substituted pyrazolopyrimidines
03/27/2012CA2513427C Compounds having anti-proliferative properties
03/27/2012CA2496203C Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
03/27/2012CA2489862C Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation
03/27/2012CA2473669C Use and preparation of dosage forms containing benzimidazole derivatives and a buffer
03/27/2012CA2454699C Method for treating primary insomnia
03/27/2012CA2447091C Methods for the treatment and prevention of pain using stress-activated protein kinase
03/27/2012CA2421087C Antisense insulin-like growth factor binding protein (igfbp)-2 oligodeoxynucleotides for prostate and other endocrine tumor therapy
03/27/2012CA2406179C Use of defibrotide and at least one haematopoietic factor to mobilize haematopoietic progenitors
03/27/2012CA2400244C Antiadhesive carbohydrates comprising a terminal uronic acid unit containing a carbon-carbon double bond
03/27/2012CA2389570C Methods for treating mild cognitive impairment
03/27/2012CA2371922C Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
03/27/2012CA2282721C A transgenic coagulation factor xiii defective animal and its use for testing wound healing and bleeding
03/27/2012CA2245496C Receptor protein designated 2f1
03/27/2012CA2230029C Multi-subtype fiv vaccines
03/22/2012WO2012037563A1 Compositions of abscisic acid for animal health
03/22/2012WO2012037562A2 Pharmaceutical and nutraceutical compositions of abscisic acid
03/22/2012WO2012037561A1 Animal feed compositions of abscisic acid
03/22/2012WO2012037553A2 Use of pkc-iota inhibitors for the treatment of breast cancer
03/22/2012WO2012037508A2 Antibacterial agents: high-potency myxopyronin derivatives
03/22/2012WO2012037499A1 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
03/22/2012WO2012037490A1 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
03/22/2012WO2012037485A2 Methods of inhibiting alphavirus replication and treating alphavirus infection
03/22/2012WO2012037484A1 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
03/22/2012WO2012037475A1 Novel compositions and methods
03/22/2012WO2012037466A2 Methods and compositions for protection cells and tissues from computed tomography radiation
03/22/2012WO2012037453A1 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
03/22/2012WO2012037411A2 Estrogen receptor modulators and uses thereof
03/22/2012WO2012037410A2 Estrogen receptor modulators and uses thereof
03/22/2012WO2012037393A1 Piperidinyl-substituted lactams as gpr119 modulators
03/22/2012WO2012037351A1 Compounds
03/22/2012WO2012037349A2 Compounds
03/22/2012WO2012037328A2 Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
03/22/2012WO2012037320A2 Pharmaceutical compositions
03/22/2012WO2012037311A1 Compositions containing omega-3 oil and uses thereof
03/22/2012WO2012037299A2 Fatty acid synthase inhibitors
03/22/2012WO2012037298A1 Fatty acid synthase inhibitors
03/22/2012WO2012037261A2 6-substituted demethyl-estradiol derivatives as er-beta agonists
03/22/2012WO2012037259A1 Novel inhibitors of hepatitis c virus replication
03/22/2012WO2012037254A1 MODIFIED iRNA AGENTS
03/22/2012WO2012037239A1 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
1 ... 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 ... 7860